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Abstract
Background: In October 2009, the French government organized a national-wide, free of charge vaccination campaign
against pandemic H1N1 influenza virus, especially targeting pregnant women, a high risk group for severe illness. The study
objective was to evaluate pandemic flu vaccine uptake and factors associated with non-vaccination in a population of
pregnant women.
Methodology/Principal Findings: In a prospective cohort conducted in 3 maternity hospitals in Paris, 882 pregnant women
were randomly included between October 12, 2009 and February 3, 2010, with the aim to study characteristics of pandemic
influenza during pregnancy. At inclusion, socio-demographic, medical, obstetrical factors and those associated with a higher
risk of flu exposition and disease-spreading were systematically collected. Pandemic flu vaccine uptake was checked until
delivery. 555 (62.9%) women did not get vaccinated. Determinants associated with non-vaccination in a multivariate logistic
regression were: geographic origin (Sub-Saharan African origin, adjusted Odd Ratio aOR=5.4[2.3–12.7], North African origin,
aOR=2.5[1.3–4.7] and Asian origin, aOR=2.1[1.7–2.6] compared to French and European origin) and socio-professional
categories (farmers, craftsmen and tradesmen, aOR=2.3[2.0–2.6], intermediate professionals, aOR=1.3[1.0–1.6], employees
and manual workers, aOR=2.5[1.4–4.4] compared to managers and intellectual professionals). The probability of not
receiving pandemic flu vaccine was lower among women vaccinated against seasonal flu in the previous 5 years
(aOR=0.6[0.4–0.8]) and among those who stopped smoking before or early during pregnancy (aOR=0.6[0.4–0.8]). Number
of children less than 18 years old living at home, work in contact with children or in healthcare area, or professional contact
with the public, were not associated with a higher vaccine uptake.
Conclusions/Significance: In this cohort of pregnant women, vaccine coverage against pandemic 2009 A/H1N1 flu was low,
particularly in immigrant women and those having a low socio-economic status. To improve its effectiveness, future
vaccination campaign for pregnant women should be more specifically tailored for these populations.
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Introduction
In June 2009, World Health Organization (WHO) raised the
pandemic alert level to the highest level of 6. Although this
pandemic was not at the scale expected by the public health
services, it can be used as an example of a general mobilization of
national health systems in a global campaign of vaccination [1].
For these reasons, data from the French 2009–2010 vaccination
campaign can be used to improve the coverage and effectiveness of
a future vaccination campaign in case of a new influenza
pandemic.
According to numerous studies, pregnant women are consid-
ered to be at higher risk of severe illness from seasonal [2,3] and
pandemic influenza [4,5,6,7]. Therefore, WHO [8], American
Centers for Disease Control and Prevention of Disease (CDC) [9],
European Centre for the Control and Prevention Diseases
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20900(ECDC) [10], European Commission, Health Security Committee
(HSC)/ Early Warning and Response System (EWRS) [11], and
the French Advisory Council for Public Health (HCSP) [12] define
pregnancy as a high-risk priority group for vaccination. French
authorities recommended pandemic H1N1 vaccination with a
single dose of an adjuvanted-free vaccine (PanenzaH) for all
pregnant women after the first trimester [13].
The vaccination campaign began in France on November 9,
2009, according to an order of priority for people at risk of severe
illness as predefined by the HCSP [12,14]. The vaccination was
administered, free of charge, in centers dedicated to pandemic
vaccine. On November 20, 2009, PanenzaH was available and
pregnant women asked to get vaccinated. The objective of the
French strategy was to cover 85% of the overall French population
[15]. The outcome of the campaign showed that, on January 18,
2010, only 7.95% of the French population was vaccinated and
only 22.7% of pregnant women [16].
These data raise the question of possible disparities in vaccine
coverage among the French pregnant women. Although vaccina-
tion was available and free for all, some socio-demographic
characteristics may have influenced women’s decision toward
vaccination. Moreover, some factors that would normally promote
vaccination such as the working conditions (e.g in contact with the
public, children or the medical community), obstetrical and medical
characteristics, may also modulate women’s awareness of vaccine’s
usefulness in the high-risk population of pregnant women.
The objective of this study was to evaluate pandemic flu vaccine
uptake and to analyze the determinants related to the non-
vaccination against the pandemic flu virus in a population of
pregant women. The data of 882 pregnant women randomly
included in a prospective cohort study conducted during the 2009
French vaccination campaign were used to address this question.
Methods
Participants
COFLUPREG ÆÆCOhort on FLU during PREGnancyææ is a
prospective study conducted in three tertiary maternity centers in
Paris, France, to determine the clinical expression, the biological
characteristics,and the maternal-fetal impact of pandemic influenza
A/H1N1 occurring during pregnancy. Between October 12, 2009
and February 3, 2010, 919 pregnant women were randomly drawn
among pregnant women that were followed in these maternity
hospitals, in order to include 45 women each day and to obtain a
representative sample of pregnant women followed in these
maternity hospitals. Women aged $18 years, speaking and
understanding French were eligible to participate if they were
pregnant between 12 and 35 weeks of gestation and followed in one
of the three maternity participating to the study. Main exclusion
criteria werea virologicallydocumentedH1N1 influenzaduringthe
last 6 months and vaccination against influenza A/H1N1 before
inclusion. From the 919 pregnant women included in COFLU-
PREGstudy,37wereexcludedduetowithdrawalofconsent(n=3),
delivery before the date of vaccine availability (n=8), and loss of
follow up (i.e. women who gave birth in another hospital and have
had less than 3 follow-up visits) (n=26). Thus, data from 882
pregnant women were included to study determinants associated
with non-vaccination against A/H1N1 influenza virus.
Procedures
At inclusion in the study the following data were collected:
socio-demographic characteristics (mother age, geographic origin,
lifestyle (single or couple), socio-professional category), medical
factors (co-morbidity associated with a high-risk of occurrence of
severe form of flu, flu symptoms since the beginning of pregnancy,
seasonal flu vaccination in the previous 5 years, smoking),
obstetrical characteristics (gestational age, gestity, twin pregnancy,
parity, significant obstetrical history and current pregnancy
complication) and factors associated with a higher risk of viral
exposition and disease-spreading (number of children under 18
years old at home, work in contact with children, healthcare
workers and professional with consistent contact with the public).
Co-morbidity associated with a risk of occurrence of severe flu
was defined by the presence of at least one of the following
diseases: chronic lung disease (including asthma), severe cardiop-
athy, severe chronic nephropathy, severe neuropathy, severe
myopathy, sickle-cell disease, diabetes mellitus, immunodeficiency,
morbid obesity and alcoholism with chronic hepatopathy.
Significant obstetric history was defined as having at least one of
the following events: late miscarriage (between 14
th and 21
th+6
days weeks of gestation), preterm delivery (between 22
th and
36
th+6 days weeks of gestation), and history of pre-eclampsia/
gestational hypertension, intrauterine growth restriction, fetal
malformation or fetal death. Current pregnancy complication
was defined as having at least one of the following complications:
placenta prævia, pyelonephritis, pre-eclampsia/gestational hyper-
tension, gestational diabetes mellitus, suspicion of intrauterine
growth restriction, fetal malformation, threatened preterm delivery
and premature rupture of membranes (PROM).
The women were followed by doctors or midwifes with monthly
visits until delivery. During each visit, information on the
occurrence of vaccination against 2009 A/H1N1, of flu symptoms
or documented A/H1N1 infection were prospectively collected.
Ethics
Written informed consent was obtained from each woman
before enrollment. The protocol was conducted in accordance
with the Declaration of Helsinki and French law for biomedical
research, and was approved by the ‘‘Ile-de-France 3’’ Ethics
Committee (Paris, France), on October 2, 2009; nu09-12075.
Statistical methods
For each variable, the choice of the reference class was made as
in adequacy with literature. The reference class was the one
known to have the highest vaccination rate. When the knowledge
did not exist in literature, the reference was the class with the
highest frequency.
Data management and statistical analysis were done using
STATA for Windows (Version 10.0 College Station, Texas, USA).
To compare numbers and percentages, we used Chi2 test or
Fisher’s exact test if n,5 and predicted n,5.
Associations between determinants and the non-vaccination
against pandemic flu were analyzed using univariate analysis.
Determinants with a p-value less than 0.20 on univariate analysis
were included in the final logistic regression. Population
characteristics differed between the three maternity hospitals.
For this reason, a cluster model was used by adjusting the logistic
regression model on the maternity center. This adjustment was
achieved by including the estimated variances Huber / White /
sandwich [17] into the logistic regression model. A systematic
research of interaction between determinants with a p-value less
than 0.20 on univariate analysis was performed.
Results
Study population
The demographic profiles and the clinical characteristics of the
study population are described in Table 1. Median age was 32.7
Vaccination Determinants against Pandemic Flu
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20900Table 1. Characteristics of the study population and determinants associated with non-vaccination against pandemic 2009 A/
H1N1 influenza: univariate analysis.
Total
n=882 (%)
Vaccinated
n=327 (%)
Non Vaccinated
n=555 (%) p-value{
Maternity hospital
Saint Vincent de Paul 233 (26.4) 108 (46.4) 125 (53.7)
Port Royal 431 (48.9) 132 (30.6) 299 (69.4)
Necker Brune 218 (24.7) 87 (39.9) 131 (60.1) ,0.01
Inclusion month
October 215 (24.4) 92 (42.8) 123 (57.2)
November 338 (38.3) 189 (55.9) 149 (44.1)
December 215 (24.4) 39 (18.1) 176 (81.9)
January 111 (12.6) 7 (6.3) 104 (93.7)
February 3 (0.3) 0 3 (100) ,0.01
{{
Age, years
18–24 40 (4.5) 7 (17.5) 33 (82.5)
25–34 547 (62.0) 206 (37.7) 341(62.3)
$35 295 (33.5) 114 (38.6) 181 (61.4) 0.03
Geographic origin
French, European 657 (74.5) 281 (42.8) 376 (57.2)
Sub-Saharan African 49 (5.56) 6 (12.2) 43 (87.7)
North African 89 (10.1) 17 (19.1) 72 (80.9)
Asian and Other* 87 (9.9) 23 (26.4) 64 (73.6) ,0.01
Lifestyle*
Single 60 (6.8) 10 (16.7) 50 (83.3)
Couple 821 (93.2) 317 (38.6) 504 (61.4) ,0.01
Socio-professional category*
Farmers/craftsmen and tradesmen 33 (3.8) 10 (30.3) 23 (69.7)
Managers, intellectual professionals 371 (42.1) 168 (45.3) 203 (54.7)
Intermediate professionals 209 (23.7) 80 (38.3) 129 (61.7)
Employees and manual workers 158 (17.9) 44 (27.9) 114 (72.2)
Unemployed people 110 (12.5) 25 (22.7) 85 (77.3) ,0.01
Number of children under 18 years old at home
0 429 (48.6) 157 (36.6) 272 (63.4)
1 314 (35.6) 125 (39.8) 189 (60.2)
.1 139 (15.8) 45 (32.4) 94 (67.6) 0.31
Job characteristic
Work in contact with the children
- Yes 88 (10.0) 32 (36.4) 56 (63.6)
- No 794 (90.0) 295 (37.2) 499 (62.9) 0.88
Healthcare worker
- Yes 89 (10.1) 36 (40.5) 53 (59.6)
- No 793 (89.9) 291 (36.7) 502 (63.3) 0.49
Professionals in contact with the public
- Yes 403 (45.7) 146 (36.2) 257 (63.7)
- No 479 (54.3) 181 (37.8) 298 (62.2) 0.63
Seasonal vaccination in the previous 5 years**
Yes 99 (11.3) 47 (47.5) 52 (52.5)
No 781 (88.8) 279 (35.7) 502 (64.3) 0.02
Smoking**
No 671 (76.3) 243 (36.2) 428 (63.8)
Stopping smoking before or early in pregnancy 115 (13.1) 52 (45.2) 63 (54.8)
Vaccination Determinants against Pandemic Flu
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primiparous, 14.2% had at least one co-morbidity and 11% had
at least one significant obstetric history. The median term of
pregnancy was 37.7 weeks of gestation [min: 22.4; max: 40.3]. Of
the 882 pregnant women, 555 (62.9%) did not get pandemic A/
H1N1 vaccine.
Factors associated with pandemic A/H1N1 vaccine
uptake
Univariate analysis (Table 1). Socio-demographic
determinants significantly associated with the non-vaccination
against 2009 A/H1N1 influenza virus were maternal age,
geographic origin, lifestyle, and socio-professional categories.
Occurrence of a flu symptom since the beginning of the
pregnancy was associated with a lack of 2009 A/H1N1 influenza
vaccination (p=0.04). On the opposite, no association was found
between vaccine uptake and the presence of a co-morbidity
associated with higher risk of severe viral infection (p=0.14).
Obstetric factors, significantly associated with 2009 A/H1N1
influenza non-vaccination, were twin pregnancy and significant
obstetric history. None of the current pregnancy complications
was significantly associated with non-vaccination.
The lack of seasonal flu vaccination in the previous 5 years and
smoking during pregnancy were correlated with A/H1N1 non-
vaccination. None of the factors associated with a higher risk of
exposition and disease-spreading to the virus (i.e. high number of
children under 18 living at home or job characteristics) was
associated with influenza A/H1N1 non-vaccination.
Multivariate analysis (Table 2). Factors associated with a
lack of vaccination against pandemic flu were geographic origin
(Sub-Saharan African origin, adjusted Odd Ratio (OR) 5.4, 95%
CI [2.3–12.7], North African origin, adjusted OR 2.5, 95% CI
[1.3–4.7] and Asian origin, adjusted OR 2.1, 95% CI [1.7–2.6]
compared to French and European origin), socio-professional
categories (farmers, craftsmen and tradesmen, adjusted OR 2.3,
95% CI [2.0–2.6], intermediate professionals, adjusted OR 1.3,
Table 1. Cont.
Total
n=882 (%)
Vaccinated
n=327 (%)
Non Vaccinated
n=555 (%) p-value{
Yes** 94 (10.7) 32 (34.0) 62 (66.0) 0.15
- ,10/d 71 (77.2) 24 (33.8) 47 (66.2)
- 10–19/d 14 (15.2) 4 (28.6) 10 (71.4)
- .19/d 7 (7.6) 2 (28.6) 5 (71.4) 0.90
Gestational age at inclusion (gestational weeks)
,22 515 (58.4) 193 (37.5) 322 (62.5)
[22–28] 186 (21.1) 68 (36.6) 118 (63.4)
.28 181 (20.5) 66 (36.5) 115 (63.5) 0.96
Gestity
1 288 (32.7) 112 (38.9) 176 (61.1)
.1 594 (67.4) 215 (36.2) 379 (63.8) 0.44
Twin pregnancy
Yes 39 (4.4) 21 (53.9) 18 (46.2)
No 843 (95.6) 306 (36.3) 537 (63.7) 0.03
Parity
0 419 (47.5) 155 (37.0) 264 (63.0)
$1 463 (52.5) 172 (37.2) 291 (62.9) 0.96
At least one associated co-morbidity
Yes 125 (14.2) 39 (31.2) 86 (68.8)
No 757 (85.8) 288 (38.0) 469 (62.0) 0.14
Significant obstetrical history
Yes 97 (11.0) 27 (27.8) 70 (72.2)
No 785 (89.0) 300 (38.2) 485 (61.8) 0.05
Current pregnancy complication
Yes 32 (3.6) 14 (43.8) 18 (56.3)
No 850 (96.4) 313 (36.8) 537 (63.2) 0.43
Flu symptoms before the inclusion
Yes 80 (9.1) 38 (47.5) 42 (52.5)
No 802 (90.9) 289 (36.0) 513 (64.0) 0.04
{Chi 2, p-value,0.20, included in the final logistic regression model.
{{Fischer exact Test.
*1 missing value.
**2 missing values.
doi:10.1371/journal.pone.0020900.t001
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2.5, 95% CI [1.4–4.4] compared to managers, intellectual
professionals). The probability of not receiving A/H1N1 vaccine
was lower among women vaccinated against seasonal flu in the
previous 5 years (adjusted OR 0.6, 95% CI [0.4–0.8]) and among
women who stopped smoking before or early during pregnancy
(adjusted OR 0.6, 95% CI [0.4–0.8]) in comparison with non-
smoking women (Table 2). The non–vaccination rate significantly
increased after November (December, adjusted OR 7.5, 95% CI
[6.9–8.2], January adjusted OR 35.4, 95% CI [10.8–116],
compared to November).
Discussion
Our study showed that, despite strong recommendations for
vaccination against pandemic flu of pregnant women, a large
proportion (62.9%) of pregnant women did not get the vaccine,
particularly immigrant women and women having a low socio-
economic status.
The percentage of non-vaccinated women is close to the
estimation published by the French Institute for Public Health
(InVS) reporting 77.3% of non-vaccinated pregnant women
against pandemic flu [16]. The low vaccination coverage against
influenza A/H1N1 in France and others countries could be partly
explained by the controversy on the safety and efficacy of
pandemic vaccines, and by a lack of knowledge about the risks
of complications and mortality of influenza A/H1N1 [15,18,19].
In France, vaccination was performed in specifically dedicated
centers located in non-medical public centers or gymnasiums, a
fact that certainly reduced the convenience of the procedure and
most of all the ability of family physicians to directly provide
medical information promoting vaccination [20,21,22]. Indeed, in
the United States, the percentage of pregnant women vaccinated
was higher when vaccination was proposed by family physicians or
healthcare professionals [18,23]. However, other factors might
have influenced pregnant women’s decision regarding vaccination.
For this reason, our study provides valuable complementary
information about determinants of non-vaccination against the
pandemic 2009 A/H1N1 influenza in pregnant women.
We found that foreign geographic origin was significantly
associated with non-vaccination against pandemic flu. Previous
studies have indeed shown a seasonal flu vaccine coverage
disparity depending on geographic origin [24,25]. This disparity
can be explained by a lack of access to information among
foreign populations or reticence about Occidental medicines. It
has also been shown that a key determinant of vaccination access
was the rate of vaccine reimbursement [26]. However since the
vaccine was free and available for all in France, economical
concerns should not have interfered with the choice of getting
Table 2. Determinants associated with non-vaccination
against pandemic 2009 A/H1N1 influenza: multivariate cluster
analysis including all determinants with a p-value,0.20 in the
univariate analysis.
Variables
Odds-Ratios brut
95%Confidence
Interval
Adjusted OR
95%CI
With Cluster
Inclusion month
October, n=215 1.7 [1.2–2.4] 2 [1.7–2.3]
November, n=338 11
December, n=215 5.7 [3.7–8.9] 7.5 [6.9–8.2]
January, n=111 18.8 [7.8–45.5] 35.4 [10.8–116]
February, n=3 ..
Age, years
18–24, n=40 2.8 [1.2–6.6] 1.6 [0.3–9.1]
25–34, n=547 1 1
$35, n=295 1.0 [0.7–1.3] 0.9 [0.7–1.2]
Geographic origin
French, European, n=657 11
Sub-Saharan African, n=49 5.4 [2.2–12.9] 5.4 [2.3–12.7]
North African, n=89 3.2 [1.8–5.5] 2.5 [1.3–4.7]
Asian and Other, n=87 2.1 [1.3–3.4] 2.1 [1.7–2.6]
Lifestyle*
Single, n=60 3.1 [1.6–6.3] 2.2 [1.0–5.1]
Couple, n=821 1 1
Socio-professional category*
Farmers/craftsmen and
tradesmen, n=33
1.9 [0.9–4.1] 2.3 [2.0–2.6]
Managers, intellectual
professionals, n=371
1 1
Intermediate professionals,
n=209
1.3 [0.9–1.9] 1.3 [1.0–1.6]
Employees and manual workers,
n=158
2.1 [1.4–3.2] 2.5 [1.4–4.4]
Unemployed people, n=110 2.8 [1.7–4.6] 2.3 [0.8–6.6]
Seasonal vaccination in the
previous 5 years**
Yes, n=99 0.6 [0.4–0.9] 0.6 [0.4–0.8]
No, n=781 11
Smoking**
No, n=671 1 1
Stopping smoking before
or early in pregnancy, n=115
0.7 [0.5–1.0] 0.6 [0.4–0.8]
Yes**, n=94 1.1 [0.7–1.7] 1.2 [0.8–1.8]
Twin pregnancy
Yes, n=39 0.5 [0.3–0.9] 0.5 [0.2–1.2]
No, n=843 1 1
At least one associated
co-morbidity
Yes, n=125 1.4 [0.9–2.0] 1.2 [0.9–1.5]
No, n=757 1 1
Significant past obstetrical
history
Yes, n=97 1.6 [1.0–2.6] 1.7 [0.9–3.3]
No, n=785 1 1
Table 2. Cont.
Variables
Odds-Ratios brut
95%Confidence
Interval
Adjusted OR
95%CI
With Cluster
Flu symptom before the
inclusion
Yes, n=80 0.6 [0.4–1] 0.7 [0.3–1.5]
No, n=802 1 1
*1 missing value.
**2 missing values.
doi:10.1371/journal.pone.0020900.t002
Vaccination Determinants against Pandemic Flu
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20900vaccinated. However, low incomes socio-professional categories
did not get vaccinated as much as the other groups. This higher
reticence towards vaccination in this group may reflect lower and
biased access to medical information on vaccine benefits and
safety.
Patients with medical or obstetrical co-morbidities are known to
be a high risk group for severe pandemic flu. Thus, pregnant
women with significant co-morbidity, pathological obstetric history
or with significant disease during their current pregnancy should
have been more vaccinated. However, they were not. This
surprising trend has been evidenced elsewhere in another study
focusing on seasonal influenza vaccine [27]. This failure might
reflect a lack of awareness of healthcare professionals regarding the
risks of A/H1N1 respiratory complications among pregnant
women with medical or obstetrical co-morbidities and the
necessity to encourage them to get vaccinated.
Furthermore, pregnant women at high risk of exposition and
likewise disease-spreading should have been more vaccinated.
However, women working with the public/ with children, and
those with children living at home, were not more vaccinated than
women at low risk of exposition and disease-spreading. This failure
highlights the risk of large viral spreading beyond this group in the
whole community. ‘‘More exposition, more risk to develop severe
self-illness. More exposition, more risk to spread disease’’: such
strong messages should be more firmly diffused to the general
population, including healthcare workers who did not get
significantly more vaccinated than other working groups despite
easier access to medical information. These surprising results were
consistent with previous studies that have established this same
lack of significant relationship between healthcare workers status
and higher level of seasonal influenza vaccination [3,21,27]. It
may results from misinformation/misunderstanding about the
safety and efficacy of vaccines, which should be improved in case
of future pandemic flu vaccination campaign.
In addition, pregnant women who had a seasonal flu
vaccination in the previous 5 years got more vaccinated than
those who did not had seasonal vaccination in the previous 5 years.
Globally, patients that believed in the safety and efficacy of
seasonal vaccination were more likely vaccinated against pan-
demic influenza. Other studies have observed similar trends
among people vaccinated against seasonal influenza who were
more prone to get vaccinated the following years [20,27]. This
factor reveals that once one gets vaccinated, he is less reluctant to
get vaccinated again. Therefore, an effort on vaccination
communication by the media for a year could have a positive
impact on revaccination during the following years.
The non–vaccination rate of pregnant women significantly
increased after November. On November 20
th, 2009, when the
vaccination campaign for pregnant women began, the fear of A/
H1N1 Influenza complications was at its maximum. Misinforma-
tion induced a vaccination drop that could partially explain the
increased non–vaccination rate in pregnant women after Novem-
ber. Furthermore, only non-vaccinated women could be included
in the cohort, a bias which may explain the lower vaccine coverage
for women included after November.
To our knowledge, only one Turkish survey that was conducted
in only 314 pregnant women with a very low rate of vaccination
(8.9%) studied few sociological, demographic and medical
determinants to access pandemic influenza vaccination [22]. The
only significant determinant associated with non-vaccination was
the occupation: working pregnant women being more vaccinated
than pregnant housewives.
Data from the COFLUPREG prospective cohort allow us to
study numerous determinants associated with the vaccination
against 2009 H1N1 influenza. A large number (882) of women
were randomly included and followed-up throughout the pan-
demic. They were interviewed monthly regarding their vaccina-
tion status. This design and the quality of the data reinforce the
reliability of the results.
We studied the determinants associated with the effective
vaccination against A/H1N1 influenza and not only the intention
to get vaccinated. Two French survey-based studies have assessed
the determinants associated with the intention to get vaccinated in
the general French population [18,28]. However, the high
discrepancy between the intention to get vaccinated before the
pandemic start (61% of the French population in June 27, 2009)
[15] and the effective vaccination rate (7.95% of the French
population at the end of the pandemic) is a major limitation of
these studies [16].
Our study has several limitations. First, the pregnant women
sample comes from three university maternity hospitals in Paris.
The results such as the vaccination incidence and the socio-
demographic factors distribution cannot be extrapolated to all
French pregnant women. But, this limitation does not interfere
with the analysis of associations between studied determinants and
non-vaccination among pregnant women. Secondly, women who
accepted to participate to the COFLUPREG study were possibly
influenced to get vaccinated. Yet, this influence seems to be low
regarding the non-vaccination rate among pregnant women in our
study (62.9%) which is similar to the French national estimation
(77.3% by the InVS).
In conclusion, in a large prospective study conducted in
pregnant women during the 2009 H1N1 influenza pandemic,
the vaccination coverage against A/H1N1 influenza was low
(62.9% of non-vaccinated women), particularly in immigrant
women and those having a low socio-economic status. Our study
provides unique data analyzing the reasons for the failure of a
national vaccination campaign and yields trails for subsequent
vaccination campaigns targeting high risk populations.
Acknowledgments
We thank all the women who participated in the study, all the persons
responsible for data collection, and the ‘‘French Research Program on
Pandemic H1N1v Flu: Institut de Microbiologie et Maladies Infectieuses
(IMMI), Inserm’’.
" Inserm COFLUPREG Study Group members:
O. Launay, P. Loulergue, V. Truster, C. Villeret, M. Cervantes-
Gonzales (Centre d’Investigation Clinique de vaccinologie Cochin Pasteur,
Ho ˆpital Cochin), F. Goffinet, V. Tsatsaris, C. Le Ray, D. Cabrol
(Maternite ´ Port-Royal, Ho ˆpital Cochin), C. Charlier, M. Lecuit, O.
Lortholary (Service de maladies infectieuses, Ho ˆpital Necker Enfants
Malades), Y. Ville, S. Parat (Maternite ´ Necker-Brune, Ho ˆpital Necker-
Enfants Malades), J. Lepercq, C. Francoual (Maternite ´, Ho ˆpital Saint
Vincent de Paul), P.H. Jarreau (service de ne ´onatalogie, Ho ˆpital Cochin),
F. Rozenberg, A. Krivine (service de virologie, Ho ˆpital Cochin), M.
Leruez-Ville (service de virologie, Ho ˆpital Cochin), S. van der Werf (CNR
grippe, Institut Pasteur), JM Tre ´luyer (service de pharmacologie, Ho ˆpital
Cochin), F. Batteux (service d’immunologie biologique, Ho ˆpital Cochin),
M.L. Gougeon (Unite ´ ÆÆImmunite ´ virale, biothe ´rapie et vaccinsææ, Institut
Paster).
Author Contributions
Conceived and designed the experiments: RF CLR CC J-MT FG OL.
Performed the experiments: RF CLR CC J-MT DS YV FG OL. Analyzed
the data: RF CLR CA VT. Contributed reagents/materials/analysis tools:
RF CLR CA. Wrote the paper: RF CLR FG OL.
Vaccination Determinants against Pandemic Flu
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20900References
1. Nicoll A, McKee M (2010) ‘‘Moderate pandemic, not many dead–learning the
right lessons in Europe from the 2009 pandemic.’’ Eur J Public Health 20(5):
486–488.
2. Chapman GB, Coups EJ (1999) ‘‘Predictors of influenza vaccine acceptance
among healthy adults.’’ Prev Med 29(4): 249–262.
3. Jones TF, Ingram LA, Craig AS, Schaffner W (2004) ‘‘Determinants of influenza
vaccination, 2003–2004: shortages, fallacies and disparities.’’ Clin Infect Dis
39(12): 1824–1828.
4. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, et al.
(2009) ‘‘H1N1 2009 influenza virus infection during pregnancy in the USA.’’
Lancet 374(9688): 451–458.
5. Rasmussen SA, Jamieson DJ, Bresee JS (2008) ‘‘Pandemic influenza and
pregnant women.’’ Emerg Infect Dis 14(1): 95–100.
6. Goodnight WH, Soper DE (2005) ‘‘Pneumonia in pregnancy.’’ Crit Care Med
33(10 Suppl): S390–397.
7. Dubar G, Azria E, Tesniere A, Dupont H, Le Ray C, et al. (2010) ‘‘French
experience of 2009 A/H1N1v influenza in pregnant women.’’ PLoS One 5(10).
8. World Health Organization. (2010) ‘‘Pregnancy and pandemic influenza A (H1N1)
2009: information for programme managers and clinicians’’. Available: http://
www.who.int/csr/resources/publications/swineflu/h1n1_guidance_pregnancy.
pdf, Accessed on 2011 March 17.
9. Centers for Disease Control and Prevention (CDC). 2009 H1N1 flu. ‘‘What
Should Pregnant Women Know About 2009 H1N1 Flu (Swine Flu)’’ (2009)
Available: http://www.cdc.gov/h1n1flu/guidance/pregnant.htm, Accessed on
2011 March 17.
10. European Centre for Disease Prevention and Control (ECDC). ‘‘Use of specific
pandemicinfluenzavaccinesduringtheH1N12009’’(2009) Available:http://www.
ecdc.europa.eu/en/publications/Publications/0908_GUI_Pandemic_Influenza_
Vaccines_during_the_H1N1_2009_Pandemic.pdf. Accessed on 2011 March 17.
11. European Commission, Health Security Committee (HSC)/ Early Warning and
Response System (EWRS). ‘‘EHC/EWRS statement on Influenza A (H1N1):
target and priority groups for vaccination.’’ (2009) Available: http://ec.europa.
eu/health/ph_threats/com/Influenza/docs/HSC_EWRS_statement_en.pdf.
Accessed on 2011 March 17.
12. Haut Conseil de la Sante ´ Publique (HCSP) ‘‘Actualisation de l’avis relatif aux
recommandations sur les priorite ´s sanitaires d’utilisation des vaccins pande ´mi-
ques dirige ´s contre le virus grippal A(H1N1)v’’ (2009) [in French] Available:
http://www.hcsp.fr/docspdf/avisrapports/hcspa20091002_H1N1.pdf. Ac-
cessed on 2011 March 17.
13. Haut Conseil de la Sante ´ Publique (HCSP) AVIS ‘‘Recommandations sur les
priorite ´s sanitaires d’utilisation des vaccins pande ´miques dirige ´s contre le virus
grippal A(H1N1)v’’ (2009) [in French] Available: http://www.hcsp.fr/docspdf/
avisrapports/hcspa20090907_H1N1.pdf. Accessed on 2011 March 17.
14. French Ministry of Health, ÆÆLancement de la campagne vaccinale contre la
grippe A(H1N1) dans les centres de vaccination lundi 09 novembre 2009 (2009)
[in French] Available: http://www.sante.gouv.fr/IMG/pdf/Lancement_de_la_
campagne_vaccinale_contre_la_grippe_A_H1N1_dans_les_centres_de_vaccina-
tion.pdf Accessed on 2011 March 17.
15. Setbon M, Raude J (2010) ‘‘Factors in vaccination intention against the
pandemic influenza A/H1N1.’’ Eur J Public Health 20(5): 490–494.
16. Bone A, Guthmann JP, Nicolau J, Levy-Bruhl D (2010) ‘‘Population and risk
group uptake of H1N1 influenza vaccine in mainland France 2009–2010: results
of a national vaccination campaign.’’ Vaccine 28(51): 8157–8161.
17. Williams RL (2000) ‘‘A note on robust variance estimation for cluster-correlated
data.’’ Biometrics 56(2): 645–646.
18. Raude J, Caille-Brillet AL, Setbon M (2010) ‘‘The 2009 pandemic H1N1
influenza vaccination in France: who accepted to receive the vaccine and why?’’
PLoS Curr 2: RRN1188.
19. White SW, Petersen RW, Quinlivan JA (2010) ‘‘Pandemic (H1N1) 2009
influenza vaccine uptake in pregnant women entering the 2010 influenza season
in Western Australia.’’ Med J Aust 193(7): 405–407.
20. Schwarzinger M, Verger P, Guerville MA, Aubry C, Rolland S (2010) ‘‘Positive
attitudes of French general practitioners towards A/H1N1 influenza-pandemic
vaccination: a missed opportunity to increase vaccination uptakes in the general
public?’’ Vaccine 28(15): 2743–2748.
21. European Medicines Agency, Science Medicines Health (2010) ‘‘Twenty-second
pandemic pharmacovigilance update’’ Available: http://www.ema.europa.eu/
docs/en_GB/document_library/Report/2010/08/WC500095870.pdf Ac-
cessed on 2011 March 17.
22. Ozer A, Arikan DC, Kirecci E, Ekerbicer HC (2010) ‘‘Status of pandemic
influenza vaccination and factors affecting it in pregnant women in
Kahramanmaras, an eastern Mediterranean city of Turkey.’’ PLoS One 5(12):
e14177.
23. Centers for Disease Control and Prevention (CDC) (2010) ‘‘Seasonal Influenza
and 2009 H1N1 Influenza Vaccination Coverage Among Pregnant Women —
10 States, 2009–10 Influenza Season Weekly’’ December 3, 2010 / 59(47);1541–
1545. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5947a1.
htm Accessed on 2011 March 17.
24. Linn ST, Guralnik JM, Patel KV (2010) ‘‘Disparities in influenza vaccine
coverage in the United States, 2008.’’ J Am Geriatr Soc 58(7): 1333–1340.
25. Link MW, Ahluwalia IB, Euler GL, Bridges CB, Chu SY, et al. (2006) ‘‘Racial
and ethnic disparities in influenza vaccination coverage among adults during the
2004–2005 season.’’ Am J Epidemiol 163(6): 571–578.
26. Endrich MM, Blank PR, Szucs TD (2009) ‘‘Influenza vaccination uptake and
socioeconomic determinants in 11 European countries.’’ Vaccine 27(30):
4018–4024.
27. Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR (2002) ‘‘Cross-sectional
study on influenza vaccination, Germany, 1999–2000.’’ Emerg Infect Dis 8(12):
1442–1447.
28. Schwarzinger M, Flicoteaux R, Cortarenoda S, Obadia Y, Moatti JP (2010)
‘‘Low acceptability of A/H1N1 pandemic vaccination in French adult
population: did public health policy fuel public dissonance?’’ PLoS One 5(4):
e10199.
Vaccination Determinants against Pandemic Flu
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20900